How concentrating dependence on China upended our economy and added risk
prescription drugs
Posted inTAP
Biden’s Executive Actions to Protect Workers
Today on TAP: The president could be doing a lot more with his executive power.
Posted inMoney, Politics, and Power
Rollups: The Emerging Magic Mushroom Monopoly
Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.
Posted inHealth and Social Policy
Biden Regulators Take Action on Hidden Pharma Monopolies
A proposed rule would eliminate the ability of pharmacy benefit managers to extract profits after a prescription drug is sold.
Posted inMoney, Politics, and Power
Project Censored, Part 2: The New Normal Is More Normalized Censorship
Canary Mission’s blacklists, union busting at Google, Pfizer’s vaccine negotiation tactics, police dogs, and forced sterilization round out the list of censored stories.
Posted inMoney, Politics, and Power
Project Censored, Part 1: The New Normal Is More Normalized Censorship
High drug costs, threats to journalists, wildcat strikes, climate debtors, and ‘forever chemicals’ in the oceans: a sobering start to this year’s list of stories you might have missed
Posted inHealth and Social Policy
The Billionaire Behind the Fight for Lower Drug Prices
A former Enron executive has poured tens of millions into national drug pricing reform. Why hasn’t it worked?
Posted inBuilding Back America
The Drug Price/Tax Break Quid Pro Quo
Democrats in high-tax states cut a deal on the Build Back Better Act.
Posted inTAP
Memo to Media: Stop Calling Manchin et al. ‘Moderates’
Today on TAP: Being more swayed by big-money contributions and an anti-mother bias are far better descriptors.
Posted inMoney, Politics, and Power
Will Biden’s FDA Be Led by a Pharma Guy?
Robert Califf—who’s worked and lobbied for the big drug companies—looks to be the front-runner for the job.